2021
DOI: 10.1016/j.bsheal.2021.11.001
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of antibiotic resistance patterns in clinical isolates of Klebsiella pneumoniae in Bangladesh

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 18 publications
(8 citation statements)
references
References 33 publications
0
4
0
Order By: Relevance
“…A nationwide AMR surveillance study in Bangladesh reported K. pneumoniae to be the third most abundant organism recovered from the clinical specimens, preceded by E. coli and pseudomonas species ( Habib et al, 2021 ). Other in-country reports suggest the proportion of MDR K. pneumoniae has increased to over 80% ( Ahmed et al, 2019 ; Aminul et al, 2021 ; Habib et al, 2021 ); this has driven the use of carbapenem as a drug of choice for treating MDR K. pneumoniae infections ( Habib et al, 2021 ). Consequently, high carbapenem resistance rates were also reported from Bangladesh ( Habib et al, 2021 ).…”
Section: Introductionmentioning
confidence: 99%
“…A nationwide AMR surveillance study in Bangladesh reported K. pneumoniae to be the third most abundant organism recovered from the clinical specimens, preceded by E. coli and pseudomonas species ( Habib et al, 2021 ). Other in-country reports suggest the proportion of MDR K. pneumoniae has increased to over 80% ( Ahmed et al, 2019 ; Aminul et al, 2021 ; Habib et al, 2021 ); this has driven the use of carbapenem as a drug of choice for treating MDR K. pneumoniae infections ( Habib et al, 2021 ). Consequently, high carbapenem resistance rates were also reported from Bangladesh ( Habib et al, 2021 ).…”
Section: Introductionmentioning
confidence: 99%
“…was most prominent in urine, sputum, and throat and was resistant to Doxycycline (27.3%), Cefixime (13.6%), Cefuroxime (13.6%), Ceftazidime (13.6%), Ciprofloxacin (13.6%), Levofloxacin (13.6%), Ampicillin (13.6%), Imipenem (13.6%), and Meropenem (13.6%). Aminul et al (2021) stated Klebsiella isolates from clinical specimens exhibited significant resistance against aminoglycosides, β-lactam antibiotics, Carbapenem, Ciprofloxacin, Cotrimoxazole, Piperacillin, and Tazobactam [17]. Clinical Klebsiella isolates were found to be resistant, ranging from 65 to 79%, against Cefepime, Cefixime, Cefuroxime, Cefotaxime, Ceftazidime, and Ceftriaxone by Tanniet al (2021) [18].…”
Section: Discussionmentioning
confidence: 99%
“…Recently, K. pneumoniae of MDR as well as those with carbapenem-resistance have developed as main public health dilemma in the world [24]. The pathogenicity of K. pneumoniae is attributed to numerous virulence factors, such as its capability to readily acquire multiple antibiotics resistance [25]. This bacterium has evolved many mechanisms to avoid β-lactam drugs, including cephalosporins, penicillins and carbapenems.…”
Section: Sadeq and Laftamentioning
confidence: 99%